Officials from the communities that host Travis Air Force Base in northern California are considering several projects to support the installation.Under one proposal, Solano County would issue bonds to finance the construction of a civil engineering facility that would allow the base to consolidate more than 50 scattered engineering operations and buildings, reported the Daily Republic. A new facility would make the base more efficient and free up space needed for flight operations, said Vacaville Mayor Len Augustine, who traveled to Washington, D.C., last week with colleagues from Fairfield and the county to promote Travis on Capitol Hill and at the Pentagon.The budget for the project, which does not yet have a specific timeline, is between $20 million and $30 million, Augustine said.“Our plan is we want to move forward with the base as quickly as possible,” said David White, city manager for Fairfield.The delegation also discussed plans to develop a 70-acre parcel under the Air Force Community Partnership Program. The plan is intended to provide a new source of revenue for the installation through a lease for the property.“Nothing is on paper, so anything is possible,” Augustine said. “But I don’t think it would be housing. It would more likely be commercial and maybe some light industrial.”The delegation also discussed efforts to secure a more reliable water source for Travis. With several of the base’s existing sources expected to end, the installation intends to develop more groundwater sources. At the same time, Travis is discussing the possibility of obtaining a secondary water source from Fairfield or Vacaville, according to the story. Dan Cohen AUTHOR
Meghan MarkleGetty ImagesMeghan Markle may not have been the Queen’s favourite after all. Though the Queen is gracious and cordial to the Duchess of Sussex when they are in public, it seems that the Queen’s affection is all for the cameras.According to the claims of a documentary, the “grandmotherly love” the monarch showed could have been a PR exercise. Being part of the Royal Family comes with its own set of advantages and disadvantages, one of these disadvantages being that the members of the Royal Family are always under the scrutiny of the media. Meghan Markle has been a part of the Royal Family only for a little while, which makes her a novice in Royalty’s public relations.The Queen, on the other hand, is a veteran at handling and presenting a Royal image to the world. Now according to reports, the Queen and Meghan Markle have an amicable relationship where Meghan apparently refers to the monarch as “Mama” in private. However, according to the documentary “Harry and Meghan: the first 100 days”, the Queen’s warm behaviour could be a PR exercise by the Palace. Meghan MarkleGetty ImagesMeghan Markle has been on the Queen’s radar for a while now, especially with reports of a Royal feud brewing between the Duchesses of Cambridge and Sussex. The Queen tamped down any attempt by Meghan to separate herself from the Royal family and to carve out her own path.But it seems that the Queen could be making an effort with Meghan Markle as the Palace may not want a repeat of what happened with Princess Diana. Either way, it seems the Queen and the Duchess of Sussex have many opportunities to work on their relationship. Meghan Markle is expected to give birth this month and the couple Sussex will be moving to Frogmore cottage after the arrival of the baby.
India’s largest drug-maker Sun Pharmaceutical Industries Ltd reported a 30% slump in quarterly profit on Saturday, 7 November, as sales in most of its markets fell and costs related to fixing compliance issues continued to hurt.In the company’s largest market, the United States, Sun Pharma’s sales in the quarter ended September were down 28%, which the company attributed mainly to increasing competition and a supply crunch at its Halol manufacturing plant in India.”Halol” was a key contributor to Sun Pharma’s sales, but in September, the US Food and Drug Administration (FDA) outlined a number of problems with manufacturing processes, and the company has since been working on remediating those.However, its profit has been hit for a few quarters as it had to restrict supply, and has not been getting US approvals to launch any product made at the Halol plant.The company’s Managing Director Dilip Shanghvi sought to assure analysts on a conference call on Saturday evening that remediation efforts were on track, though they aren’t yet complete, so the USFDA has not been invited for a re-inspection.”We are keeping (the FDA) updated on the progress at the agreed frequency. I think the things we have promised or assured the FDA, we are addressing,” he said. The company has not received any feedback from the FDA, he added.Halol is one of several Sun Pharma plants undergoing remediation. Five of its other plants â€” most of which it got as part of its acquisition of Ranbaxy Laboratories Ltd last year â€” are under an FDA import ban ever since the agency found a series of quality control issues at the plants.Shanghvi said the “full value” of the Ranbaxy deal would be realised by 2018.Apart from generics, the company is developing a drug to treat “psoriasis”, which is in Phase 3 clinical trials and expected to be filed for US approval in 2017.Sun Pharma reported a July-September net profit of Rs 1,107 crore ($167.4 million), down from Rs 1,572 crore a year earlier. Analysts, on average, were expecting Rs 1,308 crore, according to Thomson Reuters data.Total revenue was down 15% as sales across the countries it operates in fell. India was the only exception, where sales rose a marginal 1%.The company said currency volatilities and a decision to reduce its presence in some less-profitable areas hurt its sales in emerging and other markets during the quarter.